Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 7

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 7
---
 will expire at the Annual Meeting; • Eliav Barr , Karin Eastham and Jens Holstein were elected to the Board of Directors at our 2022 Annual Meeting of Stockholders, and their three-year terms will expire at the Annual Meeting; and • Tom Miller and Brent Shafer were appointed to the Board of Directors in September 2024, and their initial terms will expire at the Annual Meeting.

| YOUR VOTE IS IMPORTANT |
| Our Board              
 of Directors           
 recommends a           
 voteFORthis            
 proposal               |

Dr. Epstein is currently the Chair of the Board of Directors and will continue to serve in such role following the Annual Meeting. The Nominating and Corporate Governance Committee of the Board of Directors has recommended, and the Board of Directors has designated, Dr. Barr, Ms. Bhanji, Ms. Eastham, Mr. Holstein, Dr. Miller, Mr. Shafer and Mr. Stapley as the nominees for directors at the Annual Meeting to serve until the 2026 Annual Meeting or until their successors are duly elected or qualified.

#### Director Biographical Information
Names of the director nominees and the other members of the Board of Directors and certain biographical information as of April 21, 2025 are set forth below:

#### Veracyte2025 Proxy Statement7

#### Proposal One
| Marc Stapleyhas served as our Chief Executive Officer since June 1, 2021 and as a member of our Board of Directors since June 8, 2021. He served as the Chief Executive Officer of Helix, Inc., a genomics company, from 2019 to 2021. Prior to that, Mr. Stapley served in key managerial positions at Illumina, Inc., a genetic sequencing company, including as Chief Financial Officer from 2012 to 2017, as Chief Administrative Officer from 2015 to 2017, and as Executive Vice President from 2017 to 2019. From 2009 to 2012, Mr. Stapley served as Senior Vice President, Finance at Pfizer Inc., a pharmaceutical company. Mr. Stapley has served as a member of the board of directors of Glaukos Corporation, an ophthalmic medical technology company, since 2014, and has served as a member of the board of directors of Helix since 2015. Mr. Stapley holds a B.Sc. (Honors) in Mathematics from The University of Reading (England). 
 We believe that Mr. Stapley is qualified to